248 related articles for article (PubMed ID: 27174920)
1. Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.
Park SE; Yi HJ; Suh N; Park YY; Koh JY; Jeong SY; Cho DH; Kim CS; Hwang JJ
Oncotarget; 2016 Jun; 7(26):39796-39808. PubMed ID: 27174920
[TBL] [Abstract][Full Text] [Related]
2. BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
Kim Y; Kim YS; Kim DE; Lee JS; Song JH; Kim HG; Cho DH; Jeong SY; Jin DH; Jang SJ; Seol HS; Suh YA; Lee SJ; Kim CS; Koh JY; Hwang JJ
Autophagy; 2013 Dec; 9(12):2126-39. PubMed ID: 24322755
[TBL] [Abstract][Full Text] [Related]
3. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
4. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Hwang S; Kim S; Kim K; Yeom J; Park S; Kim I
BMB Rep; 2020 Nov; 53(11):576-581. PubMed ID: 32684241
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Singh N; Ramĩrez-Carvajal L; de Los Santos T; Golding MC; Long CR
J Interferon Cytokine Res; 2016 Jan; 36(1):37-47. PubMed ID: 26418342
[TBL] [Abstract][Full Text] [Related]
7. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo.
Park KE; Johnson CM; Cabot RA
Reprod Fertil Dev; 2012; 24(6):813-21. PubMed ID: 22781932
[TBL] [Abstract][Full Text] [Related]
8. EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Kim H; Choi SY; Lim J; Lindroth AM; Park YJ
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028644
[TBL] [Abstract][Full Text] [Related]
9. The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance.
Chen X; El Gazzar M; Yoza BK; McCall CE
J Biol Chem; 2009 Oct; 284(41):27857-27865. PubMed ID: 19690169
[TBL] [Abstract][Full Text] [Related]
10. G9a inhibition induced PKM2 regulates autophagic responses.
Ahmad F; Dixit D; Joshi SD; Sen E
Int J Biochem Cell Biol; 2016 Sep; 78():87-95. PubMed ID: 27417236
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
[TBL] [Abstract][Full Text] [Related]
12. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
13. EHMT2 is a metastasis regulator in breast cancer.
Kim K; Son MY; Jung CR; Kim DS; Cho HS
Biochem Biophys Res Commun; 2018 Feb; 496(2):758-762. PubMed ID: 29337058
[TBL] [Abstract][Full Text] [Related]
14. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
Cho HS; Kelly JD; Hayami S; Toyokawa G; Takawa M; Yoshimatsu M; Tsunoda T; Field HI; Neal DE; Ponder BA; Nakamura Y; Hamamoto R
Neoplasia; 2011 Aug; 13(8):676-84. PubMed ID: 21847359
[TBL] [Abstract][Full Text] [Related]
16. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
Wojtala M; Macierzyńska-Piotrowska E; Rybaczek D; Pirola L; Balcerczyk A
Pharmacol Res; 2018 Feb; 128():252-263. PubMed ID: 29113759
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of autophagy by the methyltransferase G9a.
Artal-Martinez de Narvajas A; Gomez TS; Zhang JS; Mann AO; Taoda Y; Gorman JA; Herreros-Villanueva M; Gress TM; Ellenrieder V; Bujanda L; Kim DH; Kozikowski AP; Koenig A; Billadeau DD
Mol Cell Biol; 2013 Oct; 33(20):3983-93. PubMed ID: 23918802
[TBL] [Abstract][Full Text] [Related]
19. EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Chen TQ; Hu N; Huo B; Masau JF; Yi X; Zhong XX; Chen YJ; Guo X; Zhu XH; Wei X; Jiang DS
Int J Biol Sci; 2020; 16(7):1252-1263. PubMed ID: 32174799
[TBL] [Abstract][Full Text] [Related]
20. BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.
Li Q; Wang L; Ji D; Bao X; Tan G; Liang X; Deng P; Pi H; Lu Y; Chen C; He M; Zhang L; Zhou Z; Yu Z; Deng A
Invest New Drugs; 2021 Jun; 39(3):686-696. PubMed ID: 33387131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
